Molecular pathways in colorectal cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1423-1431

  Al Sohaily, Sam ^a,b,d   Biankin, Andrew ^a,b,e   Leong, Rupert ^b,e   Kohonen Corish, Maija ^a,c   Warusavitarne, Janindra ^a,f  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d CAMPBELLTOWN HOSPITAL   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Chromosomal instability; Colorectal cancer; CpG Island Methylator Phenotype; Microsatellite instability; Molecular pathways

Indexed keywords

CISPLATIN; FLUOROURACIL; K RAS PROTEIN; WNT PROTEIN;

ADENOMATOUS POLYP; ALLELE; CANCER GENETICS; CANCER INVASION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME 17P; CHROMOSOME 5Q; CHROMOSOME 8P; COLORECTAL CANCER; CPG ISLAND; DEGRADATION KINETICS; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL CANCER; GENE LOSS; HAMARTOMATOUS POLYPOSIS SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYPERPLASTIC POLYPOSIS SYNDROME; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MYH ASSOCIATED POLYPOSIS; ONCOGENE; PEUTZ JEGHERS SYNDROME; PHENOTYPE; POLYPOSIS; PRIORITY JOURNAL; REVIEW; TUMOR GENE; UBIQUITINATION;

EID: 84865391382     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07200.x     Document Type: Review

References (105)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
3. Australian Institute of Health and Welfare. Cancer in Australia: An Overview, 2008. Canberra, Australia: AIHW, 2008.
4. Australian Institute of Health and Welfare. Health System Expenditures on Cancer and Other Neoplasms in Australia 2000-01. Canberra: AIHW, 2005.
5. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol. Clin. North Am. 2008; 37: 1-24, v.
6. Wei EK, Colditz GA, Giovannucci EL, Fuchs CS, Rosner BA. Cumulative risk of colon cancer up to age 70years by risk factor status using data from the Nurses' Health Study. Am. J. Epidemiol. 2009; 170: 863-72.
7. Power DG, Gloglowski E, Lipkin SM. Clinical genetics of hereditary colorectal cancer. Hematol. Oncol. Clin. North Am. 2010; 24: 837-59.
8. Speicher MR, Geigl JB, Tomlinson IP. Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. Lancet Oncol. 2010; 11: 890-8.
9. Daley D. The identification of colon cancer susceptibility genes by using genome-wide scans. Methods Mol. Biol. 2010; 653: 3-21.
10. Le Marchand L. Genome-wide association studies and colorectal cancer. Surg. Oncol. Clin. N. Am. 2009; 18: 663-8.
11. Winawer SJ, Zauber AG, Fletcher RH etal. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-85.
12. Jass JR, Whitehall VLJ, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123: 862-76.
13. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
14. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-30.
15. Penegar S, Wood W, Lubbe S etal. National study of colorectal cancer genetics. Br. J. Cancer 2007; 97: 1305-9.
16. Bodmer WF, Bailey CJ, Bodmer J etal. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987; 328: 614-16.
17. Kinzler KW, Nilbert MC, Su LK etal. Identification of FAP locus genes from chromosome 5q21. Science 1991; 253: 661-5.
18. Groden J, Thliveris A, Samowitz W etal. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
19. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J. Rare Dis. 2009; 4: 22. Available at URL: http://www.ojrd.com/content/4/1/22.
20. Groen EJ, Roos A, Muntinghe FL etal. Extra-intestinal manifestations of familial adenomatous polyposis. Ann. Surg. Oncol. 2008; 15: 2439-50.
21. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am. J. Gastroenterol. 2006; 101: 385-98.
22. Nieuwenhuis MH, Vasen HFA. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit. Rev. Oncol. Hematol. 2007; 61: 153-61.
23. Beroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1996; 24: 121-4.
24. Luchtenborg M, Weijenberg MP, Roemen GMJM etal. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 2004; 25: 1219-26.
25. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol. 2000; 18: 1967-79.
26. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-58.
27. Lipton L, Halford SE, Johnson V etal. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res. 2003; 63: 7595-9.
28. Nielsen M, Franken PF, Reinards THCM etal. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J. Med. Genet. 2005; 42: e54.
29. Desai TK, Barkel D. Syndromic colon cancer: lynch syndrome and familial adenomatous polyposis. Gastroenterol. Clin. North Am. 2008; 37: 47-72, vi.
30. Cunningham D, Atkin W, Lenz H-J etal. Colorectal cancer. Lancet 2010; 375: 1030-47.
31. Vasen HFA. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment. Pharmacol. Ther. 2007; 26 (Suppl. 2): 113-26.
32. Barrow E, Robinson L, Alduaij W etal. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin. Genet. 2009; 75: 141-9.
33. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-6.
34. Umar A, Boland CR, Terdiman JP etal. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004; 96: 261-8.
35. Nystrom-Lahti M, Parsons R, Sistonen P etal. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am. J. Hum. Genet. 1994; 55: 659-65.
36. Nicolaides NC, Papadopoulos N, Liu B etal. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80.
37. Kolodner RD, Tytell JD, Schmeits JL etal. Germ-line msh6 mutations in colorectal cancer families. Cancer Res. 1999; 59: 5068-74.
38. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 1146-58.
39. Ligtenberg MJL, Kuiper RP, Chan TL etal. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet. 2009; 41: 112-17.
40. Starr TK, Allaei R, Silverstein KAT etal. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009; 323: 1747-50.
41. Smith G, Carey FA, Beattie J etal. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 9433-8.
42. Goel A, Arnold CN, Niedzwiecki D etal. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003; 63: 1608-14.
43. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138: 2059-72.
44. Sheffer M, Bacolod MD, Zuk O etal. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 7131-6.
45. Thiagalingam S, Laken S, Willson JK etal. Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 2698-702.
46. Wang J-Y, Wang Y-H, Jao S-W etal. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol. Rep. 2006; 16: 1245-52.
47. Pajkos G, Kiss I, Sandor J, Ember I, Kishazi P. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res. 2000; 20: 1695-701.
48. Brink M, de Goeij AFPM, Weijenberg MP etal. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24: 703-10.
49. Powell SM, Zilz N, Beazer-Barclay Y etal. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-7.
50. Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 2002; 66: 131-44.
51. Bellacosa A. Genetic hits and mutation rate in colorectal tumorigenesis: versatility of Knudson's theory and implications for cancer prevention. Genes Chromosomes Cancer 2003; 38: 382-8.
52. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol. Cell. Biol. 2007; 27: 7551-9.
53. Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem. Soc. Trans. 2005; 33: 672-5.
54. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25: 7531-7.
55. Fukuyama R, Niculaita R, Ng KP etal. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene 2008; 27: 6044-55.
56. Kohonen-Corish MRJ, Sigglekow ND, Susanto J etal. Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene 2007; 26: 4435-41.
57. Pangon L, Sigglekow ND, Larance M etal. The "Mutated in Colorectal Cancer" protein is a novel target of the UV-induced DNA damage checkpoint. Genes Cancer 2010; 1: 917-26.
58. Chughtai SA, Crundwell MC, Cruickshank NR etal. Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 1999; 18: 657-65.
59. Mourra N, Zeitoun G, Portier G etal. High-resolution genotyping of chromosome 8 in colon adenocarcinomas reveals recurrent break point but no gene mutation in the 8p21 region. Diagn. Mol. Pathol. 2008; 17: 90-3.
60. Macartney-Coxson DP, Hood KA, Shi H-J etal. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 2008; 8: 187; Available at URL: http://www.biomedcentral.com/1471-2407/8/187.
61. Vogelstein B, Fearon ER, Hamilton SR etal. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319: 525-32.
62. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 2002; 3: 101-28.
63. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-30.
64. Lanza G, Matteuzzi M, Gafa R etal. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int. J. Cancer 1998; 79: 390-5.
65. Ogunbiyi OA, Goodfellow PJ, Herfarth K etal. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J. Clin. Oncol. 1998; 16: 427-33.
66. Wang W, Wang G-Q, Sun X-W etal. Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma. World J. Gastroenterol. 2010; 16: 6026-34.
67. Zhang H, Duan HO, Kirley SD, Zukerberg LR, Wu C-L. Aberrant splicing of cables gene, a CDK regulator, in human cancers. Cancer Biol. Ther. 2005; 4: 1211-15.
68. Park DY, Sakamoto H, Kirley SD etal. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. Am. J. Pathol. 2007; 171: 1509-19.
69. Martin M, Simon-Assmann P, Kedinger M etal. DCC regulates cell adhesion in human colon cancer derived HT-29 cells and associates with ezrin. Eur. J. Cell Biol. 2006; 85: 769-83.
70. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998; 395: 801-4.
71. McDermott U, Longley DB, Johnston PG. Molecular and biochemical markers in colorectal cancer. Ann. Oncol. 2002; 13 (Suppl. 4): 235-45.
72. Shiou S-R, Singh AB, Moorthy K etal. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res. 2007; 67: 1571-9.
73. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87.
74. Boland CR, Thibodeau SN, Hamilton SR etal. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-57.
75. Nardon E, Glavac D, Benhattar J etal. A multicenter study to validate the reproducibility of MSI testing with a panel of 5 quasimonomorphic mononucleotide repeats. Diagn. Mol. Pathol. 2010; 19: 236-42.
76. Kohonen-Corish MRJ, Daniel JJ, Chan C etal. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J. Clin. Oncol. 2005; 23: 2318-24.
77. Iacopetta B, Grieu F, Amanuel B. Microsatellite instability in colorectal cancer. Asia Pac. J. Clin. Oncol. 2010; 6: 260-9.
78. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam. Cancer 2004; 3: 93-100.
79. Warusavitarne J, Ramanathan P, Kaufman A, Robinson BG, Schnitzler M. 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. Int. J. Colorectal Dis. 2006; 21: 625-31.
80. Carethers JM, Chauhan DP, Fink D etal. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-31.
81. Aebi S, Kurdi-Haidar B, Gordon R etal. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996; 56: 3087-90.
82. Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr. Med. Assoc. J. 2005; 7: 520-4.
83. Sargent DJ, Marsoni S, Monges G etal. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. [Erratum appears in J. Clin. Oncol. 2010 (Oct 20); 28 (30): 4664]. J. Clin. Oncol. 2010; 28: 3219-26.
84. Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int. J. Colorectal Dis. 2007; 22: 739-48.
85. Des Guetz G, Schischmanoff O, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 2009; 45: 1890-6.
86. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer 2010; 46: 2788-98.
87. Soreide K, Janssen EAM, Soiland H, Korner H, Baak JPA. Microsatellite instability in colorectal cancer. Br. J. Surg. 2006; 93: 395-406.
88. Deng G, Bell I, Crawley S etal. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 2004; 10: 191-5.
89. Markowitz S, Wang J, Myeroff L etal. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
90. Parsons R, Myeroff LL, Liu B etal. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995; 55: 5548-50.
91. Wong JJL, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007; 56: 140-8.
92. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin. Cancer Biol. 1999; 9: 349-57.
93. Samowitz WS, Albertsen H, Sweeney C etal. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl. Cancer Inst. 2006; 98: 1731-8.
94. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 8681-6.
95. Weisenberger DJ, Siegmund KD, Campan M etal. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006; 38: 787-93.
96. Nosho K, Irahara N, Shima K etal. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008; 3: e3698.
97. Jover R, Nguyen T-P, Perez-Carbonell L etal. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140: 1174-81.
98. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am. 2008; 37: 25-46, v.
99. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol. 2009; 4: 343-64.
100. Place RJ, Simmang CL. Hyperplastic-adenomatous polyposis syndrome. J. Am. Coll. Surg. 1999; 188: 503-7.
101. Lindor NM. Hereditary colorectal cancer: MYH-associated polyposis and other newly identified disorders. Best Pract. Res. Clin. Gastroenterol. 2009; 23: 75-87.
102. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002; 2: 442-54.
103. Brabletz T, Hlubek F, Spaderna S etal. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179: 56-65.
104. Iwatsuki M, Mimori K, Yokobori T etal. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101: 293-9.
105. Cano A, Perez-Moreno MA, Rodrigo I etal. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000; 2: 76-83.